Nektar Therapeutics NKTR Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's operating lease liabilities (current)?
- Nektar Therapeutics (NKTR) reported operating lease liabilities (current) of $22.53M in Q1 2026.
- How has Nektar Therapeutics's operating lease liabilities (current) changed year-over-year?
- Nektar Therapeutics's operating lease liabilities (current) increased by 3.2% year-over-year, from $21.84M to $22.53M.
- What is the long-term trend for Nektar Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Nektar Therapeutics's operating lease liabilities (current) has grown at a 8.1% compound annual growth rate (CAGR), from $13.92M to $20.5M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.